Novo-Nordisk ADR repsg 1 B logo

Novo-Nordisk ADR repsg 1 B

Stock
Stock
ISIN: US6701002056
Ticker: NVO
US6701002056
NVO

Price

Price

Historical dividends and forecast

All dividend data

Novo-Nordisk ADR repsg 1 B has so far distributed $1.447 in 2024. The next dividend will be paid on 02.04.2025


$0.22

CHART BY

Frequently asked questions

What is Novo-Nordisk ADR repsg 1 B's market capitalization?

The market capitalization of Novo-Nordisk ADR repsg 1 B is $351.57B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Novo-Nordisk ADR repsg 1 B's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Novo-Nordisk ADR repsg 1 B is 34.82. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Novo-Nordisk ADR repsg 1 B?

Novo-Nordisk ADR repsg 1 B's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.979. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Novo-Nordisk ADR repsg 1 B's stock?

Currently, 28 analysts cover Novo-Nordisk ADR repsg 1 B's stock, with a consensus target price of $132.18. Analyst ratings provide insights into the stock's expected performance.

What is Novo-Nordisk ADR repsg 1 B's revenue over the trailing twelve months?

Over the trailing twelve months, Novo-Nordisk ADR repsg 1 B reported a revenue of $38.02B.

What is the EBITDA for Novo-Nordisk ADR repsg 1 B?

Novo-Nordisk ADR repsg 1 B's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $18.71B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Novo-Nordisk ADR repsg 1 B?

Novo-Nordisk ADR repsg 1 B has a free cash flow of $3.22B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Novo-Nordisk ADR repsg 1 B's stock?

The 5-year beta for Novo-Nordisk ADR repsg 1 B is 0.89. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Novo-Nordisk ADR repsg 1 B have, and what sector and industry does it belong to?

Novo-Nordisk ADR repsg 1 B employs approximately 71,880 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Novo-Nordisk ADR repsg 1 B's shares?

The free float of Novo-Nordisk ADR repsg 1 B is 3.14B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$351.57B

5Y beta

 
0.89

EPS (TTM)

 
$2.979

Free Float

 
3.14B

P/E ratio (TTM)

 
34.82

Revenue (TTM)

 
$38.02B

EBITDA (TTM)

 
$18.71B

Free Cashflow (TTM)

 
$3.22B

Pricing

1D span
$101.45$106.00
52W span
$94.74$148.14

Analyst Ratings

The price target is $132.18 and the stock is covered by 28 analysts.

Buy

18

Hold

8

Sell

2

Information

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

71,880

Biotechnology & Drugs

Health Care

Identifier

ISIN

US6701002056

Primary Ticker

NVO

Knockouts

Join the conversation